Werewolf Therapeutics Inc (HOWL)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.97+2.38%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · HOWL
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Operating Expenses & Income | |||||||
| R&D Expenses | 32.9 | 44.8 | 56.4 | 41.8 | 53.8 | 35.3 | 16.6 |
| Operating Income | (31.3) | (60.7) | (73.6) | (40.5) | (56.1) | (50.1) | (22.4) |
| Earnings from Continuing Operations | |||||||
| Interest Expense | — | 5.3 | 4.7 | 3.1 | 0.0 | — | — |
| Interest & Investment Income | 2.0 | 3.1 | 6.7 | 7.4 | 1.9 | — | — |
| Net Interest Expenses | — | — | — | (4.3) | (1.9) | — | — |
| Other Non-Operating Income / Expenses | (3.4) | (0.1) | 3.1 | 3.1 | 2.2 | 0.1 | 7.4 |
| Net Income | |||||||
| Net Income | (34.6) | (60.8) | (70.5) | (37.4) | (53.8) | (50.0) | (15.0) |
| Per Share | |||||||
| Basic EPS | (0.71) | (1.32) | (1.63) | (1.05) | (1.86) | (10.94) | (28.08) |
| Diluted EPS | (0.71) | (1.33) | (1.63) | (1.05) | (1.86) | (10.94) | (28.08) |
| Basic Weighted Avg Shares | 48.6 | 46.0 | 43.3 | 35.6 | 28.9 | 18.5 | 1.0 |
| Diluted Weighted Avg Shares | 48.6 | 46.8 | 43.9 | 35.6 | 28.9 | 18.5 | 1.0 |
| Supplemental | |||||||
| EBIT | (31.3) | (60.7) | (73.6) | (40.5) | (56.1) | (50.1) | (22.4) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.